{
  "id": "60259b661cb411341a0000b2",
  "type": "summary",
  "question": "What is the outcome of COVID-19 patients treated with tocilizumab?",
  "ideal_answer": "Preliminary clinical results have indicated that tocilizumab can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33262810"
  ],
  "snippets": [
    {
      "text": " Preliminary clinical results have indicated that antagonism of the IL-6 receptor (IL-6R), including with the FDA-approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33262810",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}